US FDA Communication Ahead Of Major Actions Could Counter Misinformation, Ex-Official Says

 
• By Kate Rawson
Josh Sharfstein speaks during Prevision Policy's 2021 BioPharma Congress
Josh Sharfstein argues that FDA should be more proactive in combating misinformation. • Source: Biopharma Congress screenshot

More from US FDA

More from Agency Leadership